Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2007_648 | Other Identifier | Merck Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the efficacy of anacetrapib (100 mg) for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assess the safety and tolerability of anacetrapib (100 mg) in participants with CHD/CHD risk-equivalent disease on stable dose regimen of statin with or without other lipid-modifying therapy. The two year extension to this study will further evaluate the long-term safety profile and efficacy of anacetrapib in CHD/CHD-risk equivalent patients who are on ongoing therapy with a statin with or without other lipid-modifying therapy.
The 76 week treatment period is followed by a 12 week reversibility phase which can be extended by up to another 12 weeks in order to allow participants who have completed their week 88 visit to continue in the study until the Extension study is ready to be implemented.
In the optional extension, participants will be assigned to the same treatment arm to which they were assigned in the base study. The total duration of the extension study will be up to 116 weeks; which will include a 2 year treatment period, followed by a 12 week reversal phase. A post-extension study follow-up phone call will be completed 12 weeks after discontinuation or completion of study treatment. Participants previously treated with anacetrapib or placebo will be invited in a 4:1 ratio in an optional extended reversal phase. The total duration of the extended reversal phase will be 1 year.
Participants previously treated with anacetrapib in the DEFINE study will be followed periodically for up to 4 years to determine plasma levels of anacetrapib. Participants will also be invited to participate in a sub-study consisting of one clinic visit to measure anacetrapib levels in the plasma and the subcutaneous adipose tissue.
ACRONYM: DEFINE= Determining the EFficacy and Tolerability of Cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anacetrapib | Experimental | Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension. |
|
| Placebo | Placebo Comparator | Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| anacetrapib | Drug | Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Low Density Lipoprotein Cholesterol | Baseline and 24 weeks | |
| Number of participants with hepatitis-related adverse experiences | Through 88 weeks | |
| Number of participants with Alanine Transaminase consecutive elevations greater than or equal to 3xULN (Upper Limit of Normal) | Through 88 weeks | |
| Number of participants with Aspartate Aminotransferase consecutive elevations greater than or equal to 3xULN | Through 88 weeks | |
| Number of participants with Creatine Phosphokinase elevations greater than or equal to 10xULN | Through 88 weeks | |
| Number of participants with Creatine Phosphokinase elevations greater than or equal 10xULN with muscle symptoms | Through 88 weeks | |
| Number of participants with sodium, chloride, or bicarbonate elevations greater than ULN | Through 88 weeks | |
| Number of participants with reduction in potassium levels less than LLN (Lower Limit of Normal) | Through 88 weeks | |
| Number of participants with myalgia | Through 88 weeks | |
| Number of participants with rhabdomyolysis |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in High Density Lipoprotein Cholesterol | Baseline, 24 weeks, and 76 weeks | |
| Change from baseline in non-High Density Lipoprotein Cholesterol | Baseline, 24 weeks, and 76 weeks |
Not provided
Inclusion Criteria:
Base Study:
Extension Study:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25670362 | Derived | Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4. | |
| 24737712 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: placebo | Drug | Participants will receive one placebo tablet once daily for 76 weeks. |
|
| Through 88 weeks |
| Number of participants with pre-specified adjudicated cardiovascular serious adverse events | Through 88 weeks |
| Number of participants with death from any cause | Through 88 weeks |
| Number of participants with significant increase in Blood Pressure | Through 88 weeks |
| Change from baseline in Apolipoprotein B | Baseline, 24 weeks, and 76 weeks |
| Change from baseline in Apolipoprotein A-1 | Baseline, 24 weeks, and 76 weeks |
| Change from baseline in Low Density Lipoprotein Cholesterol | Baseline, 24 weeks, and 76 weeks |
| Derived |
| Gotto AM Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):543-9. doi: 10.1177/1074248414529621. Epub 2014 Apr 14. |
| 21082868 | Derived | Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. |
| 19781408 | Derived | Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028. |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C530884 | anacetrapib |
Not provided
Not provided
Not provided